The relative roles of D, and D, dopamine receptor stimulation in mediating the antiparkinsonian effects of dopaminergic drugs remain unclear. To determine the functional metabolic consequences of selective dopamine receptor stimulation, we used 2-deoxyglucose (2-DG) autoradiography to examine the effects of the D, agonist SKF-38393 and the D, agonist LY-171555 on regional cerebral glucose utilization (RCGU) in rats with unilateral 6-hydroxydopamine (6-OHDA) substantia nigra lesions. .0 mg/ kg) and LY-171555 (0.01-5.0 mg/kg) produced indistinguishable behavioral responses, including vigorous contralateral rotation. Treatment with each drug similarly increased glucose utilization, dose-dependently, in the parafascicular thalamus, subthalamic nucleus, deep layers of the superior colliculus, and lateral midbrain reticular formation ipsilateral to the nigral lesion; glucose utilization was decreased in the ipsilateral lateral habenula. By contrast, the D, and D, agonists differentially altered glucose utilization in the entopeduncular nucleus (EP) and the substantia nigra pars reticulata (SN,). SKF-38393,5.0 and 25.0 mg/kg, increased glucose utilization 127 and 275%) respectively, in the pars reticulata ipsilateral to the lesion. LY-171555,l .O and 5.0 mg/kg, caused maximal contralateral turning, yet did not alter glucose utilization in the ipsilateral SN,. The glucose utilization response of the ipsilateral EP paralleled that of the SN, demonstrating large increases following administration of SKF-38393 and minimal change following the use of LY-171555. The results demonstrate that the selective D, agonist reproduces the marked glucose utilization increases (2-3-fold above control values) in the EP and SN, that were previously observed using L-DOPA and apomorphine in this model, whereas the selective D, agonist does not. Because both nuclei are selectively rich in D, receptors, with D,:D, ratios of 20-30:1, the data suggest that the glucose utilization increases observed with L-DOPA result, at least in part, from a direct stimulation of D, receptors in these nuclei and do not reflect an exclusive drug effect on striatal dopamine receptors.
Given the magnitude of the glucose utilization response, the findings suggest that D, receptors in the EP Received Dec. 29, 1986; revised Mar. 30, 1987; accepted Mar. 31, 1987 and SN, become functionally supersensitive following 6-OHDA substantia nigra lesion. The ability of selective D, and D, agonists to differentially regulate metabolic activity in these 2 major basal ganglia output nuclei may be of physiologic and therapeutic significance.
Degeneration of dopaminergic neurons in the substantia nigra and the resultant dopamine deficiency in the basal ganglia represent the critical neuropathological and neurochemical correlates of Parkinson's disease (Hornykiewicz, 1982) . The most effective therapy for Parkinson's disease remains dopamine replacement, in the form of precursor L-DOPA or direct-acting dopamine agonists (e.g., bromocriptine, pergolide). Some fundamental questions remain regarding the mechanism of action of these drugs: (1) Which dopamine receptors (i.e., anatomic localization or receptor subtype) need to be stimulated to achieve an antiparkinsonian effect? (2) Subsequent to dopamine receptor stimulation, which neural circuits are activated to mediate these effects?
In an attempt to answer this second question, the 2-deoxyglucose (2-DG) autoradiographic method of measuring regional cerebral glucose utilization (RCGU) has been used to identify brain regions physiologically altered by dopaminergic drugs. L-DOPA and apomorphine (a D, and D, agonist) produce indistinguishable RCGU patterns when administered systemically to rats with unilateral 6-hydroxydopamine (6-OHDA) lesions of the substantia nigra, a classical animal model of Parkinson's disease (Ungerstedt et al., 1973) . This pattern is characterized by marked RCGU increases (-200%) in the entopeduncular nucleus (EP; homolog of the primate medial pallidum) and substantia nigra pars reticulata (SN,) ipsilateral to the nigral lesion, and moderates RCGU changes (-1 O-50%) in other brain regions (Wooten and Collins, 1983; Trugman and Wooten, 1986) . It has been hypothesized that these profound glucose utilization changes in the EP and SN, reflect primarily increased physiological activity in the axon terminals of striatal projection neurons (Trugman and Wooten, 1986) . This is consistent with studies suggesting that the striatum is the primary site of dopamine receptor supersensitivity and dopaminergic drug action following the loss of nigral dopamine neurons (Ungerstedt, 1971; Siggins et al., 1976; Creese et al., 1977) .
In recent years, it has become clear that endogenous dopamine interacts with 2 distinct receptors, D, and D,, as identified by both biochemical and pharmacological criteria (Stoof and Kebabian, 1984 Controls are lesioned rats treated with saline (n = 6). The experimental groups consist of lesioned rats treated with SKF-38393 or LY-17 I555 (n = 3). Behavior was observed for 60 set every 5 min and 360" contralateral rotations were expressed as means i SD. Postural asymmetry was graded as absent (0), mild (+; 10'30" head tilt), or marked (+ +; tight head to tail posture). Facial grooming was rated as absent (0) (Boyson et al., 1986; Dawson et al., 1986 ; Savasta paminergic drugs alter motor behavior and achieve antiparkinet al., 1986) .
At present, the functional role of each receptor sonian effects via D,-receptor stimulation (Schachter et al., 1980;  Controls are lesioned rats treated with saline (n = 6). The experimental groups consist of lesioned rats treated with SKF-38393 or LY-17 1555 (n = 3) at the indicated doses. Data are means f SD of the ratio of gray to white matter optical density (OD& Dunnett's test (df = 7,19) was used to compare experimental group OD, values to control values for each brain region. Statistical significance is indicated: * p < 0.05; ** p i 0.0 1. Seeman, 1980) . Studies employing recently developed selective D, and D, agonists and antagonists, however, have suggested that the D, receptor mediates some of the behavioral effects of dopaminergic drugs both in normal animals and in those with 6-OHDA or reset-pine-induced dopamine depletion (Rosengarten et al., 1983; Molloy and Waddington, 1984; Arnt, 1985; Braun and Chase, 1985; Breese et al., 1985a, b) .
To determine the functional metabolic consequences of selective dopamine receptor stimulation, we have examined the effects of the D, agonist SKF-38393 (Setler et al., 1978; Sibley et al., 1982) and of the D, agonist LY-171555 (Tsuruta et al., 198 1) on RCGU in rats with unilateral nigral lesions. We present evidence that these selective agonists, while producing similar glucose utilization patterns in multiple brain regions, differentially alter glucose utilization in the EP and SN,. (Wooten and Collins, 1981) . Six-hydroxydopamine hydrobromide (6.0 &2.0 ~1 of 0.5% ascorbic acid in saline) was injected over 3 min at the following stereotactic coordinates: bregma -5.0.mm AP, 1.6 mm L, -8.0 mm DV (Paxinos and Watson, 1982) . Rats were tested 10 d later with anomorphine hydrochloride (Sigma), 0.5 mg/kg, i.p., to determine les;on efficacy. Only rats that turned a minimum of 5 rotations/min at the peak action ofapomorphine were used in subsequent 2-DG studies, performed 4-6 weeks after lesioning.
Racemic (RS) SKF-38393 (1-phenyl-2,3,4,5-tetrahydro-( lH)-3-benzazenine-7.8-diol hvdrochloride: Research Biochemicals, Wayland, MA) was-dissolved in NaCl, 77 m6, containing 10% (vol/vol) propylene glycol. LY-17 1555 [trans-(-)-4aR-4,4a,5,6,7,8,8a ,9-octahydro-5-propylJH(or 2H)-pyrazolo-3,4-g-quinoline, monohydrochloride] (quinpyrrole; Lilly Research Laboratories, Indianapolis, IN) was dissolved in saline. Each rat received 25 PCi of 14C-2-deoxyglucose (55 pCi/mmol; American Radiochemical, St. Louis, MO) reconstituted in saline. All drugs, vehicle. and isotooe were iniected intravenously in a volume of 1 ml/kg body 'weight. Drug doses are expressed in terms of the weights of their salts.
14C-2-DG autoradiography was performed according to the method of Sokoloff et al. (1977) . The experimental groups consisted of unilateral nigral-lesioned rats treated with SKF-38393 or LY-17 1555. The control group consisted oflesioned rats treated with saline. On the experimental day, after the rats had fasted overnight, a central venous catheter was inserted under 1% halothane anesthesia. After 3 hr of recovery, rats were iniected with a drug followed bv 14C-2-DG 1 min later. Unrestrained rats were studied in 23 x 35 cm cages. Behavioral observations, which included observation of the number of 360" contralateral rotations, were recorded for 60 set every 5 min. Postural asymmetry was graded as absent (O), mild (+; 10-30" head tilt), or marked (+ +; tight head to tail position). Facial grooming was rated as absent (0) or present (+). Forty-five minutes after the 14C-2-DG injection, the rats were killed with a 50 mg/ml intravenous bolus of sodium pentobarbital. The brains were rapidly removed, frozen in liquid freon, and mounted on brass chucks. Duplicate 20 ym coronal sections were taken every 140 pm, thaw-mounted on coverslips, dried on a 60°C warming tray, and exposed to Kodak SB-5 x-ray film for 6 d. Film autoradiographs were analyzed with a Leitz variable aperture microdensitometer.
Data analysis. Data for glucose utilization were expressed as a ratio of gray matter optical density (OD) to white matter (corpus callosum) OD (OD,) (Sharp et al., 1983; Mitchell and Crossman, 1984) . The data represent the mean +-SD of a minimum of 4 measurements per brain region per animal. All OD values were between 0.05 and 0.9 and were therefore on the linear part ofthe OD-versus-tissue equivalent 14C curve (Sharp et al., 1983) . Analvsis of variance revealed no difference among groups for the corpus cahosum OD values (df= 7,19).
Dunnett's multiple t test was used to compare OD, data from the experimental groups to those ofcontrols. A test ofhomogeneity ofslopes was used to compare the regression lines of the log dose-response data.
A paired t test was used to compare ipsilateral and contralateral OD, values in the lesioned controls. Statistical significance was taken asp < 0.05.
Results
Behavioral observations Behavioral observations made during the 45 min circulation time of the 14C-2-DG are summarized in Table 1 . The doses of both and LY-17 1555 produced effects ranging from minimal behavioral change to vigorous contralateral rotation. In those rats that received the higher doses, turning behavior always began within 30-60 set of completion of the intravenous injection.
Locomotor activity was minimal in those rats that didn't turn; they generally remained stationary throughout the experimental period. Intermediate doses of both drugs produced mild postural asymmetry without contralateral rotation. At these doses, a distinctive facial grooming behavior, using predominantly the forelimb contralateral to the substantia nigra lesion, was noted. This behavior was elicited by both drugs. At doses of each drug that elicited vigorous contralateral turning, facial grooming was not observed. As indicated in Table 1 , the administration of SKF-38393 and LY-17 1555 produced comparable behavioral effects over the indicated dose ranges.
Regional cerebral glucose utilization
The effects of the substantia nigra lesion alone (control) and the effects of SW-38393 and LY-171555 on RCGU are presented in Table 2 . The substantia nigra lesion resulted in characteristic RCGU changes in several brain regions ipsilateral to the lesion: globus pallidus (up 20%), lateral habenula (up 22%), subthalamic nucleus (down 1 l%), and multiple cortical regions (down 5-10%). These findings are consistent with prior reports (Kozlowski and Marshall, 1980; Wooten and Collins, 198 1).
Both D, (SKF-38393) and D, (LY-171555) agonists produced dose-dependent RCGU changes in selected brain regions. SKF-38393, 0.5 mg/kg-a dose associated with minimal behavioral change-did not alter glucose utilization in any region studied. Administration of SKF-38393, 5.0 mg/kg resulted in mild postural asymmetry and contralateral facial grooming; it increased RCGU in the ipsilateral EP (up 56%), SN, (up 127%), and subthalamic nucleus (up 35%), and decreased RCGU in the ipsilateral lateral habenula (down 35%). RCGU was also increased in the contralateral SN, (up 23%). SKF-38393,25.0 mg/kg, caused continuous contralateral circling and RCGU changes of greater magnitude in the same regions: EP (up 1889/o), ipsilateral SN, (up 275%), contralateral SN, (up 46%), subthalamic nucleus (up 38%), and lateral habenula (down 45%). In addition, RCGU was increased in other brain regions ipsilateral to the lesion: parafascicular thalamus (up 5 lo/o), pretectal area (up 23%), deep layers of superior colliculus (up 48%), and lateral midbrain re- . Log dose-response curves for 2-DG uptake in the substantia nigra pars reticulata (SN,), entopeduncular nucleus (EP), and lateral habenula ipsilateral to the 6-OHDA SN, lesion. Lesioned rats were administered SKF-38393 (D, agonist) or LY-171555 (Dz agonist) intravenously (n = 3). The shaded area indicates 2-DG uptake in the control group (lesioned rats given saline; n = 6). For both the SN, and EP, the slopes of the D, and D, dose-response curves differ (p < 0.001) indicating that 2-DG uptake in these nuclei is differentially altered by these drugs. The slopes of the dose-response curves in the lateral habenula do not differ, indicating that 2-DG uptake in this nucleus is altered in a similar manner by both D, and D, agonists. Optical-density ratios significantly different from control values are indicated as follows: *, p < 0.05; **, p < 0.01. ticular formation (up 44%). At this dose, RCGU was also increased in the lateral striatum bilaterally (ipsilateral, up 34%; contralateral, up 26%).
LY The combination of 2-DG studies with behavioral analysis allowed for a correlation of RCGU responses with turning behavior. Only 2 brain regions, the parafascicular nucleus of the thalamus and the deep layers of the superior colliculus, demonstrated RCGU changes that correlated exclusively with tuming. Other regions, including the EP, lateral habenula, and subthalamic nucleus, demonstrated RCGU changes at drug doses associated with postural asymmetry, without overt contralateral rotation. Vigorous turning behavior was produced by LY-17 1555 without a significant RCGU change in the SN,.
It is of interest to note that certain brain regions that have been implicated in dopamine-mediated locomotor behavior did not demonstrate any RCGU changes upon administration of either SKF-38393 or LY-171555. These regions include the nucleus accumbens, motor cortex, and ventroposterior thalamus. RCGU in the globus pallidus ipsilateral to the nigral lesion showed a tendency to increase with both D, and D, agonists, but these changes did not reach statistical significance. RCGU in the striatum, the nucleus considered to be the major site of action of dopaminergic drugs following nigral lesion, was moderately increased in the lateral quadrant with treatment by SKF-38393 (25 mg/kg) (up 30% bilaterally), but remained unchanged following the administration of LY-17 1555.
Discussion
The 2-DG autoradiographic method provides a powerful means for simultaneously surveying metabolic activity in multiple brain regions and correlating these changes with behavior. In an effort to identify the neural circuits activated by the selective stimulation of D, and D, receptors, we have studied the effects of D, (SKF-38393) and D, (LY-17 1555) dopamine agonists on RCGU in rats with unilateral 6-OHDA SN, lesions. The pharmacologic selectivity of these drugs has been determined by extensive in vitro biochemical investigation (Setler et al., 1978; Tsurata et al., 1981; Sibley et al., 1982; Onali et al., 1985) . In vivo data on the inhibition of prolactin secretion suggest that pharmacologic specificity at D, and D, receptors is maintained at the doses used in this study (Setler et al., 1978; Bach et al., 1980) . The use of both SKF-38393 and LY-171555 resulted in broad and comparable ranges of behavioral and RCGU responses. While both drugs produced similar RCGU changes in several brain regions, including the lateral habenula, subthalamic nucleus, deep layers of the superior colliculus, and parafascicular thalamus, RCGU was differentially altered in the EP and the SN,. Given the strategic role of these nuclei as the dual source of basal ganglia efferents to premotor centers (Graybiel and Ragsdale, 1979) , the ability of selective D, and D, agonists to differentially regulate metabolic activity in these 2 nuclei may be of pathophysiologic and therapeutic significance.
Two key questions arise in interpreting the present findings: (1) What is the electrophysiological correlate of the RCGU changes in the EP and SN, consequent to drug administration?, and (2) upon systemic administration, where do these drugs primarily act to produce their effects? In rats with unilateral SN, lesions, both apomorphine (a mixed D, and D, agonist) and L-DOPA (a precursor to dopamine) induce contralateral rotation and marked RCGU increases in the EP and SN, (up -200%) (Wooten and Collins, 1983; Trugman and Wooten, 1986) . Electrophysiological studies have demonstrated that, in B-OHDAlesioned rats, systemically administered apomorphine profoundly and consistently inhibits the firing of identified SN, output neurons . On the basis ofevidence that the striatum is the primary site of supersensitivity following SN, lesion, it has been hypothesized that the dramatic RCGU increases in the EP and SN, reflect primarily a direct drug effect on striatal dopamine receptors (Trugman and Wooten, 1986) . Accordingly, the RCGU increases were thought to represent increased metabolic activity in the axon terminals of inhibitory striatoentopeduncular and striatonigral neurons. This speculation is consistent with known electrophysiological observations . Our present results demonstrate that administration of the selective D, agonist SKF-38393 reproduces the RCGU increases in the EP and SN, previously observed with apomorphine and L-DOPA, whereas the selective D, agonist LY-171555 does not.
Recently, the effects of D, and D, agonists on SN, neuronal activity have been reported (Weick and Walters, 1987) . When administered to rats with unilateral 6-OHDA lesions, SKF-38393 (10 mg/kg, i.v.) was found to mimic the inhibitory effects of apomorphine upon SN, neuronal activity, although the magnitude of the average inhibition was not as great. LY-171555 (1.0 mg/kg, i.v.) was much less effective in producing inhibition. The D, antagonist SCH-23390 was effective in reversing the inhibitory effects of apomorphine, whereas pretreatment with the D, antagonist YM-09 15 l-2 altered only minimally the apomorphine-induced inhibition. The electrophysiological and 2-DG studies of apomorphine and selective dopamine agonists complement each other. It is clear that one electrophysiological correlate of the marked RCGU increase in the SN, observed with apomorphine and SKF-38393 is profound inhibition of SN, neuronal activity. Together, these studies suggest that the D, receptor plays a significant role in mediating the effects of apomorphine on neuronal activity and glucose utilization in the SN,.
Recent receptor-localization studies have contributed to our understanding of where these dopaminergic drugs may be acting. Both the EP and SN, have large numbers of D, receptors and few D, receptors, with D,:D, ratios of 18: 1 and 36: 1, respectively (Boyson et al., 1986) . Lesion studies have suggested that the D, The D, receptor has been identified by both biochemical and pharmacological criteria, yet its physiological role in brain function is debated (Stoof and Kebabian, 1984) . In normal rats, the selective D, agonist SKF-38393 does not produce typical stereotyped chewing or gnawing, nor does it increase locomotor behavior; it does result in a nonstereotyped grooming behavior (Molloy and Waddington, 1984) . In rats with 6-OHDA SN, lesions, administration of SKF-38393 results in contralateral receptors in the EP and SN, are located on the terminals of rotation indistinguishable from that produced by apomorphine afferents from the striatum (Altar et al., 1986; Barone and Chase, or L-DOPA (Setler et al., 1978) . Recent work has suggested that 1986; Porceddu et al., 1986; Wamsley et al., 1986) . What might both the locomotor activity and self-mutilating behavior inbe the physiological role for these D, receptors? Morphologic duced by L-DOPA in rats treated neonatally with 6-OHDA are studies have confirmed the existence of dopamine in dendrites mediated by functionally supersensitive D, receptors (Breese et of SN, neurons, which course ventrally to densely innervate the al., 1985a, b) . Thus, behavioral studies clearly indicate a su-SN, (Bjiirklund and Lindvall, 1975) . Dopamine is physiologipersensitive response to D,-receptor stimulation in rats with tally and pharmacologically releasable from this dendritic pool, 6-OHDA lesions of dopaminergic neurons. It has been reported and its release attenuates the inhibition of SN, output neurons that SKF-38393 does not alter RCGU in naive animals (Palacios evoked by electrical stimulation of the striatonigral GABAergic and Wiederhold, 1985) . By contrast, we report that adminispathway (Cheramy et al., 198 1; Waszczak and Walters, 1986) .
tration of SKF-38393 to rats with 6-OHDA SN, lesions results Electrophysiologic evidence suggests that this modulatory role in dose-dependent RCGU changes in multiple brain regions, of dopamine in the SN, may be mediated by the D, receptor and in marked RCGU increases in the EP and SN,. This is (Matthews and German, 1986) . Interpreted in the context of the consistent with other evidence that the RCGU response to doelectrophysiological and receptor-localization studies, our data paminergic drugs varies with the state of sensitivity to dopamine suggest that the RCGU increases in the EP and SN, observed (Palacios and Wiederhold, 1986) . The mechanisms that underlie after the administration of apomorphine, L-DOPA, or SKFthis shift in the dose-RCGU-responsecurve to SKF-38393 after 38393 result, at least in part, from a direct action on D, receptors 6-OHDA lesion remain to be determined. Our RCGU results in these nuclei and may not reflect an exclusive drug effect at complement the behavioral studies and further support a role the striatal level.
for the D, receptor in mediating some of the effects of L-DOPA Supersensitivity to the behavioral effects of dopamine agoin rats with 6-OHDA lesions. nists, characterized by a left shift in the dose-response curve, It has been suggested, on the basis of behavioral and lesion occurs in patients with Parkinson's disease, and has been demstudies, that D, and D, agonists produce contralateral rotation onstrated following SN, lesion in rats (Ungerstedt, 1971; Ur- in the 6-OHDA rat model by the selective activation of anaetsky and Schoenfeld, 1971; Hornykiewicz, 1982) . Because of tomically distinct striatal efferent pathways (Herrera-Marschitz the major axonal projection of SN, dopaminergic neurons to and Ungerstedt, 1984a, b) . Inherent in the interpretation ofthese the striatum, much work has been directed toward demonstratstudies is the assumption that the striatum is the sole site of ing the existence and the molecular mechanisms of supersendopamine receptor supersensitivity and dopaminergic drug acsitivity to dopamine in this nucleus (Siggins et al., 1976 ; Creese tion following 6-OHDA SN, lesion. Our results suggest that, in et al., 1977) . Less attention has been directed to the SN, as a addition to the striatum, the EP and SN, may be major sites of potential site of supersensitivity to dopamine following SN, leaction of those dopaminergic drugs capable of stimulating the sion. The ability of iontophoretically applied dopamine to at-D, receptor (e.g., apomorphine, L-DOPA). Our data do not ditenuate SN, responses to GABA is increased 40% following rectly confirm or refute the hypothesis proposed by Herrera-6-OHDA nigral lesion, providing electrophysiologic evidence Marschitz and Ungerstedt (1984a, b) , but they do suggest that of a supersensitive dopaminergic effect in the SN, (Waszczak these additional sites of drug action need to be incorporated and . Our data suggest that a supersensitive RCGU into future models of the functional neuroanatomy of turning. response to D,-receptor stimulation exists in the EP and SN, In this study, the parafascicular nucleus of the thalamus and following SN, lesion.
the deep layers of the superior colliculus were the 2 brain regions In the present study, as in prior 2-DG studies of dopamine where significant RCGU changes correlated exclusively with agonists, the RCGU responses of the EP paralleled the responses of the SN, (Fig. 2) . These 2 nuclei have similar spontaneous firing patterns, nerve cell morphology, and afferent and efferent connections, suggesting that they represent a single nucleus divided by the internal capsule (DeLong and Georgopoulos, 1982) . In addition, they share similar D,:D, receptor profiles (Boyson et al., 1986) . The presence of large numbers of D, receptors in the EP suggests a local physiological role for dopamine, yet no dopaminergic neural processes have been demonstrated terminating in this nucleus. Our RCGU data suggest that dopaminergic drugs alter metabolic activity in the EP in part via direct stimulation of D, receptors within the nucleus, and further indicate that studies aimed at elucidating a physiologic role for dopamine in this nucleus, while technically difficult, might yield important information. rotational behavior. The parafascicular nucleus receives afferents from the SN, (Beckstead et al., 1979) and projects to the striatum (Jones and Leavitt, 1974) ; rats with unilateral lesions of the parafascicular nucleus turn ipsilaterally in response to apomorphine (Ahlenius et al., 1982) . Our RCGU data support a role for the parafascicular nucleus, in conjunction with dopamine-dependent basal ganglia circuits, in turning behavior. Metabolic activity is also increased in the deep layers of the superior colliculus during turning induced by either D, or D, agonists. Similar RCGU changes have been described consequent to the use of systemic L-DOPA (Trugman and Wooten, 1986) and intrastriatal dopamine (Brown and Wolfson, 1983) . Together, these RCGU studies further support a role of the deep layers of the superior colliculus in postural control (DiChiara et al., 1982) . The results of this study have potential clinical implications. Our results indicate that D, and D, dopamine agonists differentially alter glucose utilization in the EP and SN, in rats with SN, lesions. This assumes importance partly because these 2 regions serve as the major output nuclei of the basal ganglia (Graybiel and Ragsdale, 1979) . Bromocriptine, a dopaminergic ergot used in combination with L-DOPA for advanced Parkinson's disease, is both a D, agonist and a D, antagonist (Markstein, 198 1). Our results raise the possibility that the antagonist actions on D, receptors in the EP and SN, may contribute to the therapeutic efficacy of bromocriptine in ameliorating L-DOPA-induced dyskinesias and motor fluctuations. The demonstration of the differential regulation of metabolic activity in the EP and SN, by D, and D, agonists provides a rationale for the trial of dopamine receptor subtype-selective drugs in clinical disorders of the basal ganglia.
